ApiJect Systems, Corp.
ApiJect Systems, Corp. is a public-benefit medical technology company working to bring prefilled, single-dose injections to more people in every market. The ApiJect Platform enables pharmaceutical and biotech companies to design scalable prefilled injectors and efficiently fill-finish them with their injectable drug products. This can be done either on one of their own ApiJect-licensed Blow-Fill-Seal packaging lines or at one of our world-class manufacturing partners.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Internationally (various countries)
- Year Founded:
Every year, more than a million people across the world are killed due to syringe reuse and unsafe injection practices in healthcare facilities. ApiJect was founded to stop this tragedy.
Advancing Fill-Finish to Solve Drug Delivery Challenges for the World
Marc Koska, OBE, recognized that to address the problem of unsafe medical injections, the world needed a single-use prefilled syringe that could work in any market, and that Blow-Fill-Seal was the key to making that possible.
What he created was more than just a scalable and efficient prototype prefilled injector for global health. It was a new drug delivery platform with the potential to enable more liquid medicines and vaccines to safely reach more patients across the world.
Today, ApiJect Systems is a medical technology company working to improve how sterile liquid medicines and vaccines are fill-finished across the world.
We do this by helping pharmaceutical companies design rapidly-scalable, cost-efficient drug delivery systems, and then assist in manufacturing those devices.
Our mission is to make injectable medicines and vaccines safe and accessible to everyone. And every pharma company, contract manufacturer, healthcare provider, and nation we work with, helps bring us one step closer to that goal.
Marc Koska founds ApiJect Ltd. and begins designing BFS-based inline prefilled injectors.
Marc teams up with Jay Walker and forms ApiJect Systems, Corp. Creates the first prototype BFS-based inline prefilled injector
Work begins with U.S. Department of HHS to advance BFS-based drug delivery systems for emergency response.
Work begins with U.S. DOD to create BSL2 emergency capacity for filling COVID-19 vaccines in BFS drug delivery systems. Upgraded first BFS line within 7 months.
ApiJect begins licensing to help pharma companies and contract manufacturers fill-finish liquid drug products for use within our platform.
$111MM Equity Investment Round by Royalty Pharma and Jefferies
Awarded Top 10 Drug Delivery Suppliers